The University of Southampton
University of Southampton Institutional Repository

Bevacizumab: a new way of doing business?

Bevacizumab: a new way of doing business?
Bevacizumab: a new way of doing business?
This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.
choroidal neovascularization, impact, surgery, efficacy, therapy, 360-degree peripheral retinectomy, bevacizumab, clinical-trials, clinical-trial, treatment, macular degeneration, photocoagulation, amd, subfoveal choroidal neovascularization, eye, avastin, trial, age-related macular degeneration, management, endothelial growth-factor, translocation
0950-222X
985-987
Canning, C.
6cb6e055-58bb-4182-a690-0aaa340378e4
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Canning, C.
6cb6e055-58bb-4182-a690-0aaa340378e4
Lotery, A.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514

Canning, C. and Lotery, A. (2006) Bevacizumab: a new way of doing business? Eye, 20 (9), 985-987. (doi:10.1038/sj.eye.6702501).

Record type: Article

Abstract

This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.

Full text not available from this repository.

More information

Published date: 2006
Keywords: choroidal neovascularization, impact, surgery, efficacy, therapy, 360-degree peripheral retinectomy, bevacizumab, clinical-trials, clinical-trial, treatment, macular degeneration, photocoagulation, amd, subfoveal choroidal neovascularization, eye, avastin, trial, age-related macular degeneration, management, endothelial growth-factor, translocation

Identifiers

Local EPrints ID: 62345
URI: https://eprints.soton.ac.uk/id/eprint/62345
ISSN: 0950-222X
PURE UUID: 81f4a68a-33a2-480b-8cca-d9a324f7f7c1
ORCID for A. Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 08 Sep 2008
Last modified: 14 Mar 2019 01:44

Export record

Altmetrics

Contributors

Author: C. Canning
Author: A. Lotery ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×